NASDAQ:CDNA

CareDx - CDNA Stock Forecast, Price & News

$8.83

-0.25 (-2.75%)

(As of 03/28/2023 12:00 AM ET)

Add

Compare

Today's Range: $8.76
▼
$9.18
50-Day Range: $8.83
▼
$17.61
52-Week Range: $8.10
▼
$40.42

Volume: 752,087 shs
Average Volume: 1.47 million shs
Market Capitalization: $473.94 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $16.00

Institutional Ownership

CareDx MarketRank™ Forecast

Analyst Rating: Hold
2.40 Rating Score
Upside/Downside: 81.2% Upside
$16.00 Price Target
Short Interest: Bearish
9.87% of Float Sold Short
Dividend Strength: N/A
Sustainability: -0.66
Upright™ Environmental Score
News Sentiment: 0.37
Based on 4 Articles This Week
Insider Trading: Selling Shares
$492,669 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($1.12) to ($0.75) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.22 out of 5 stars

Medical Sector

357th out of 1,002 stocks

Medical Laboratories Industry

14th out of 26 stocks

4.2

Analyst's Opinion

Consensus Rating
CareDx has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on 2 buy ratings, 3 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $16.00, CareDx has a forecasted upside of 81.2% from its current price of $8.83.
Amount of Analyst Coverage
CareDx has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

2.0

Short Interest

Percentage of Shares Shorted
9.87% of the float of CareDx has been sold short.
Short Interest Ratio / Days to Cover
CareDx has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in CareDx has recently increased by 4.51%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
CareDx does not currently pay a dividend.
Dividend Growth
CareDx does not have a long track record of dividend growth.

4.2

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
CareDx has received a 61.52% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "DNA sequencers", "Genomics analysis tools", and "Patient flow management systems" products. See details.
Environmental Sustainability
The Environmental Impact score for CareDx is -0.66.

1.3

News and Social Media Coverage

News Sentiment
CareDx has a news sentiment score of 0.37. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for CareDx this week, compared to 4 articles on an average week.
Search Interest
Only 15 people have searched for CDNA on MarketBeat in the last 30 days. This is a decrease of -63% compared to the previous 30 days.
MarketBeat Follows
Only 7 people have added CareDx to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, CareDx insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $492,669.00 in company stock.
Percentage Held by Insiders
Only 5.00% of the stock of CareDx is held by insiders.

0.6

Earnings and Valuation

Earnings Growth
Earnings for CareDx are expected to grow in the coming year, from ($1.12) to ($0.75) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of CareDx is -6.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of CareDx is -6.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
CareDx has a P/B Ratio of 1.10. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About CareDx (NASDAQ:CDNA) Stock

CareDx, Inc. operates as a transplant diagnostics company, which discovers, develops and commercializes diagnostic solutions. Its products include AlloMap, AlloSure and Laboratory products. The company was founded on December 21, 1998 and is headquartered in Brisbane, CA.

Receive CDNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CareDx and its competitors with MarketBeat's FREE daily newsletter.

CDNA Stock News Headlines

March 28, 2023 | americanbankingnews.com

CareDx, Inc (NASDAQ:CDNA) Receives $16.00 Consensus PT from Brokerages

March 23, 2023 | finance.yahoo.com

CareDx Presents Latest Advancements at 12th Congress of the International Pediatric Transplant Association

March 28, 2023 | Behind the Markets (Ad)

Buy THIS stock before Taiwan is attacked

... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.

March 11, 2023 | finance.yahoo.com

CareDx, Inc (NASDAQ:CDNA) Q4 2022 Earnings Call Transcript

March 11, 2023 | businesswire.com

CAREDX INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of CareDx, Inc. - CDNA

March 7, 2023 | finance.yahoo.com

The American Society of Transplant Surgeons Position Statement Supports Use of CareDx’s AlloSure Kidney for Organ Transplant Surveillance

March 6, 2023 | finance.yahoo.com

CareDx Update Regarding Raymond James & Associates’ Conference

March 6, 2023 | finance.yahoo.com

CareDx To Participate in the Raymond James & Associates’ 44th Annual Institutional Investors Conference

March 28, 2023 | Behind the Markets (Ad)

Buy THIS stock before Taiwan is attacked

March 3, 2023 | businesswire.com

CareDx Comments on MolDX Publication of New Billing and Coding Article

March 1, 2023 | finance.yahoo.com

CareDx Full Year 2022 Earnings: In Line With Expectations

March 1, 2023 | finance.yahoo.com

CareDx Key Supporter of the National Kidney Foundation’s Annual Kidney Patient Summit

February 27, 2023 | finance.yahoo.com

Baron Discovery Fund Believes CareDx (CDNA) Will Reward Investors for Patience

February 27, 2023 | finance.yahoo.com

CareDx Reports Fourth Quarter and Full Year 2022 Results

February 22, 2023 | finance.yahoo.com

CareDx Showcases Clinical Value of Multimodality and AI Innovation at the American Society of Transplantation Cutting Edge of Transplantation Meeting

February 21, 2023 | finance.yahoo.com

CareDx to Report Fourth Quarter and Full Year 2022 Financial Results

February 16, 2023 | finance.yahoo.com

Earnings Preview: CareDx (CDNA) Q4 Earnings Expected to Decline

February 16, 2023 | finance.yahoo.com

CareDx Showcases Latest Advancements in Cellular Transplant and Therapy Including Specialized Digital Health Solutions at the 2023 Tandem Meetings

January 26, 2023 | finance.yahoo.com

CareDx (NASDAQ:CDNA) delivers shareholders splendid 20% CAGR over 5 years, surging 9.8% in the last week alone

January 26, 2023 | finance.yahoo.com

JACC Publication Guides Use of CareDx’s HeartCare Transplant Rejection Surveillance in Clinical Practice

January 11, 2023 | finance.yahoo.com

CareDx Fosters Transplant Innovation as Distinguished Founder’s Circle Sponsor for the 23rd Annual American Society of Transplant Surgeons State of the Art Winter Symposium

January 9, 2023 | finance.yahoo.com

CareDx Reports Preliminary Revenue Results for Fourth Quarter and Full Year 2022

December 21, 2022 | finance.yahoo.com

New ISHLT Guidelines Support Use of CareDx’s HeartCare Solutions, AlloMap and AlloSure, in Routine Monitoring of Heart Transplant Patients

December 12, 2022 | seekingalpha.com

CareDx: What To Make Of The New Share Repurchase Program (Rating Upgrade)

December 6, 2022 | finance.yahoo.com

CareDx Announces $50 Million Stock Repurchase Program

December 1, 2022 | finance.yahoo.com

Independent Prospective Study Defines Reference Range for CareDx’s AlloSure for Long-Term Lung Transplant Surveillance

November 17, 2022 | finance.yahoo.com

Here's Why CareDx (CDNA) Could be Great Choice for a Bottom Fisher

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive CDNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CareDx and its competitors with MarketBeat's FREE daily newsletter.

CDNA Company Calendar

Last Earnings: 10/28/2021
Today: 3/28/2023
Next Earnings (Estimated): 5/04/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Medical laboratories
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:CDNA
CUSIP: N/A
CIK: 1217234
Web: www.caredxinc.com
Phone: (415) 287-2300
Fax: 415-287-2450
Employees: 633
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $16.00
High Stock Price Forecast: $25.00
Low Stock Price Forecast: $9.00
Forecasted Upside/Downside: +80.6%
Consensus Rating: Hold
Rating Score (0-4): 2.40
Research Coverage: 5 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.44)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-76,610,000.00
Net Margins: -23.81%
Pretax Margin: -23.69%
Return on Equity: -17.33%
Return on Assets: -14.09%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 5.11
Quick Ratio: 4.85

Sales & Book Value

Annual Sales: $321.79 million
Price / Sales: 1.48
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $8.05 per share
Price / Book: 1.10

Miscellaneous

Outstanding Shares: 53,670,000
Free Float: 50,990,000
Market Cap: $475.52 million
Optionable: Optionable
Beta: 1.03

Key Executives

Reginald Seeto
President, Chief Executive Officer & Director

Abhishek Jain
Chief Financial & Accounting Officer

Amitabh Shukla
Senior Vice President-Technology

Sham Dholakia
Senior VP-Medical Affairs & Clinical Operations

Robert N. Woodward
Vice President-Research & Development

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

CDNA Stock - Frequently Asked Questions

Should I buy or sell CareDx stock right now?: 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for CareDx in the last year. There are currently 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" CDNA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CDNA, but not buy additional shares or sell existing shares.
View CDNA analyst ratings or view top-rated stocks.
What is CareDx's stock price forecast for 2023?: 5 analysts have issued 12 month price objectives for CareDx's shares. Their CDNA share price forecasts range from $9.00 to $25.00. On average, they expect the company's share price to reach $16.00 in the next year. This suggests a possible upside of 80.6% from the stock's current price.
View analysts price targets for CDNA or view top-rated stocks among Wall Street analysts.
How have CDNA shares performed in 2023?: CareDx's stock was trading at $11.41 on January 1st, 2023. Since then, CDNA shares have decreased by 22.3% and is now trading at $8.86.
View the best growth stocks for 2023 here.
When is CareDx's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 4th 2023.
View our CDNA earnings forecast.
How were CareDx's earnings last quarter?: CareDx, Inc (NASDAQ:CDNA) released its quarterly earnings results on Thursday, October, 28th. The company reported $0.07 earnings per share for the quarter, topping the consensus estimate of ($0.14) by $0.21. The business earned $75.60 million during the quarter, compared to analysts' expectations of $74.11 million. CareDx had a negative net margin of 23.81% and a negative trailing twelve-month return on equity of 17.33%. CareDx's revenue was up 41.6% on a year-over-year basis. During the same period in the previous year, the business posted ($0.06) earnings per share.
What ETFs hold CareDx's stock?: ETFs with the largest weight of CareDx (NASDAQ:CDNA) stock in their portfolio include ARK Genomic Revolution ETF (ARKG), Jacob Forward ETF (JFWD), ROBO Global Healthcare Technology and Innovation ETF (HTEC), Global X Genomics & Biotechnology ETF (GNOM), SPDR S&P Biotech ETF (XBI), Direxion Daily S&P Biotech Bull 3x Shares (LABU), Principal Healthcare Innovators ETF (BTEC) and First Trust Nasdaq Lux Digital Health Solutions ETF (EKG).
What guidance has CareDx issued on next quarter's earnings?: CareDx updated its FY 2023 earnings guidance on Monday, February, 27th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $328.00 million-$338.00 million, compared to the consensus revenue estimate of $338.42 million.

What other stocks do shareholders of CareDx own?: Based on aggregate information from My MarketBeat watchlists, some companies that other CareDx investors own include Block (SQ), Roku (ROKU), Exact Sciences (EXAS), NVIDIA (NVDA), Advanced Micro Devices (AMD), Tesla (TSLA), Enphase Energy (ENPH), Johnson & Johnson (JNJ), Activision Blizzard (ATVI) and Alibaba Group (BABA).
What is CareDx's stock symbol?: CareDx trades on the NASDAQ under the ticker symbol "CDNA."
Who are CareDx's major shareholders?: CareDx's stock is owned by many different institutional and retail investors. Top institutional shareholders include ARK Investment Management LLC (11.56%), ArrowMark Colorado Holdings LLC (7.48%), Sumitomo Mitsui Trust Holdings Inc. (4.79%), Nikko Asset Management Americas Inc. (4.79%), Bamco Inc. NY (3.84%) and Gagnon Securities LLC (2.79%). Insiders that own company stock include Ankur Dhingra, George Bickerstaff, Grace Colon, Michael Brian Bell, Michael Goldberg, Paul Adler, Peter Maag, Ralph Snyderman, Reginald Seeto, Sasha King, Thomas A Thomas and William A Hagstrom.
View institutional ownership trends.
How do I buy shares of CareDx?: Shares of CDNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is CareDx's stock price today?: One share of CDNA stock can currently be purchased for approximately $8.86.
How much money does CareDx make?: CareDx (NASDAQ:CDNA) has a market capitalization of $475.52 million and generates $321.79 million in revenue each year. The company earns $-76,610,000.00 in net income (profit) each year or ($1.44) on an earnings per share basis.
How many employees does CareDx have?: The company employs 633 workers across the globe.
How can I contact CareDx?: CareDx's mailing address is 1 TOWER PLACE 9TH FLOOR, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.caredxinc.com. The company can be reached via phone at (415) 287-2300, via email at caroline.corner@westwicke.com, or via fax at 415-287-2450.

This page (NASDAQ:CDNA) was last updated on 3/28/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

CareDx - CDNA Stock Forecast, Price & News

CareDx MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About CareDx (NASDAQ:CDNA) Stock

CDNA Stock News Headlines

CDNA Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

CDNA Stock - Frequently Asked Questions

Overall MarketRank^™